Biomarker conservation in primary and metastatic epithelial ovarian cancer

被引:45
|
作者
Tewari, KS
Kyshtoobayeva, AS
Mehta, RS
Yu, IR
Burger, RA
DiSaia, PJ
Fruehauf, JP
机构
[1] Oncotech Inc, Irvine, CA 92614 USA
[2] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Div Gynecol Oncol,Sect Hematol & Oncol, Orange, CA 92868 USA
关键词
ovarian cancer; biomarkers; biologic prognostic factors; clonal divergence; angiogenesis; tumor heterogeneity;
D O I
10.1006/gyno.2000.5837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The aim of this study was to compare the overexpression of specific biomarkers in primary advanced and recurrent epithelial ovarian cancers. Methods. Biomarker expression by epithelial ovarian cancer specimens from primary and metastatic sites was examined by immunohistochemistry and flow cytometry. Biomarker expression by subpopulations of tissues consisting of matched pairs of synchronous and metachronous lesions was also studied. Results. A total of 3173 epithelial ovarian cancer specimens were retrieved from women with FIGO Stage III/IV disease. These included lesions from 1036 primary and 2137 metastatic sites. The percentages of biomarker expression for primary and metastatic lesions, respectively, were MDR1, 12 and 10%; p53, 55 and 60%; HER2, 12 and 11%; EGF-R, 26 and 33%; increased microvessel counts (CD31), 21 and 36%. Approximately 73% of both primary and metastatic specimens were aneuploid, and approximately 57% of both sets had an S-phase fraction >7%. Only EGF-R and CD31 expression were found to be significantly different between the primary and metastatic tumors (P < 0.05). Of the paired synchronous cases (n = 48) evaluated, 88% of aneuploid primary lesions were associated with aneuploid metastases. Similarly, the distributions for MDR1, HER2, and p53 expression did not vary significantly between primary and metastatic sites. Pairings of metachronous cases (n = 66) revealed that nearly 80% of primary aneuploid tumors (n = 39) retained their aneuploid status at the time of relapse. Furthermore, there were no significant changes in MDR1, p53, or HER2 expression at relapse. Conclusions. With the exception of EGFR and CD31, clonal divergence of the biomarkers evaluated in this study probably does not play a significant role in imparting clinical heterogeneity during the advanced and recurrent stages of epithelial ovarian cancer. These particular genes likely undergo alterations early in the tumorigenesis process before metastases have become established, (C) 2000 Academic Press.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 50 条
  • [1] Genomic analyses of primary and metastatic serous epithelial ovarian cancer
    Israeli, O
    Gotlieb, WH
    Friedman, E
    Korach, J
    Friedman, E
    Goldman, B
    Zeltser, A
    Ben-Baruch, G
    Rienstein, S
    Aviram-Goldring, A
    CANCER GENETICS AND CYTOGENETICS, 2004, 154 (01) : 16 - 21
  • [2] Adaptations of key metabolic pathways in primary and metastatic epithelial ovarian cancer
    Bose, Shree
    Previs, Rebecca
    Berchuck, Andrew
    Shen, Xiling
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S136 - S136
  • [3] Angiogenesis in primary and metastatic epithelial ovarian carcinoma
    Abulafia, O
    Triest, WE
    Sherer, DM
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (03) : 541 - 547
  • [4] Quantification of angiogenesis in primary and metastatic epithelial ovarian carcinomas
    Wong, LF
    Fong, T
    Siddiqui, GK
    Gammell, SJ
    Kini, M
    Crow, JC
    Bamberger, ES
    Reid, WMN
    MacLean, AB
    Perrett, CW
    BRITISH JOURNAL OF CANCER, 2002, 86 : S45 - S45
  • [5] Primary metastatic Ovarian Cancer in Pregnancy
    Friedrich, Michael
    Terjung, Arne
    Steffens, Annette
    Rogmans, Gunther
    Frieling, Thomas
    Kraft, Clayton
    Hemmerlein, Bernhard
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (02) : 135 - 138
  • [6] Genetics of Primary and Metastatic Ovarian Cancer
    MacLaughlan, Shannon
    Fischer, Andrew
    Kristjansdottir, Katrin
    Ritz, Anna
    Ben Raphael
    Steinhoff, Margaret
    Brodsky, Alexander
    Brard, Laurent
    CANCER RESEARCH, 2010, 70
  • [7] The differential gene expression of Notch receptors in primary and metastatic epithelial ovarian cancer sites
    Kotsopoulos, I. C.
    Papanikolaou, A.
    Papazisis, K. T.
    Hadzidimitriou, A.
    Touplikioti, P.
    Tsolalddisl, D.
    Lambropoulos, A. F.
    Tarlatzis, B. C.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (01) : 84 - 90
  • [8] Biomarker discovery in epithelial ovarian cancer by genomic approaches
    Mok, Samuel C.
    Elias, Kevin M.
    wong, K-Kwok Wong
    Ho, Kae
    Bonome, Tomas
    Birrer, Michael J.
    ADVANCES IN CANCER RESEARCH, VOL 96, 2007, 96 : 1 - 22
  • [9] Progranulin as a prognostic biomarker of advanced epithelial ovarian cancer
    Fitzgerald, Sharon
    Yu, Minshu
    Hays, John
    Di Santo, Nicola
    Havrilesky, Laura
    Kohn, Elise
    CANCER RESEARCH, 2013, 73 (08)
  • [10] Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer
    Brakora, KA
    Lee, H
    Yusuf, R
    Sullivan, L
    Harris, A
    Colella, T
    Seiden, MV
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 361 - 365